FDA-Subject by formulation interaction (Switchability) [Regulatives / Guidelines]

posted by sudy – India, 2018-03-28 09:09 (1829 d 22:22 ago) – Posting: # 18598
Views: 3,069

Dear all,

I have a discussion point regarding switchability criteria for methylphenidate 54mg tabs (specially). For lower strength, they have removed this criterion.

As per guideline, we have to meet the ABE criteria and additionally meet 95% UB for switchability.

Now, as we are doing a fully replicate study as suggested by OGD recommendation on methylphenidate, can we use RSABE approach in case if we get ISCV-reference > 30% for any one of the PK parameter Cmax or partial AUCs, instead of using 90% CI calculation to prove the bioequivalence?

The OGD recommendation did not discuss anything about this case, as we know that methylphenidate is not a HVD. But incase if we got CV-R more than 30%, can we apply RSABE?

Your suggestion will be highly appreciated.


Complete thread:

UA Flag
 Admin contact
22,559 posts in 4,725 threads, 1,607 registered users;
14 visitors (0 registered, 14 guests [including 9 identified bots]).
Forum time: 07:31 CEST (Europe/Vienna)

The penalty for scientific irrelevance is, of course,
that the statistician’s work is ignored by the scientific community.    George E.P. Box

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz